Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Graham

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumorsC A Johnson, D Kilpatrick, R von Roemeling, et al.
Infection and Immunity|January 31, 2007
Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse modelAbiodun D Ogunniyi, Kim S LeMessurier, Rikki M A Graham, et al.
Epidemiology and Infection|March 27, 2014
Molecular characterization of an Australian serotype 1 Streptococcus pneumoniae outbreakM Staples, R M A Graham, A V Jennison, et al.
Biochemical Pharmacology|August 4, 1992
Studies on the molecular pharmacology of GR63178A. A novel pentacyclic pyrolloquinone anticancer drugJ Cummings, M A Graham, B M Hoey, et al.
Cancer Research|May 15, 1992
Phase I and pharmacokinetic study of rhizoxinD Bissett, M A Graham, A Setanoians, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancerN Kemeny, W Tong, M Gonen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksS Senan, R Rampling, M A Graham, et al.
Cancer Research|August 1, 1997
Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxiaE O Aboagye, R J Maxwell, A B Kelson, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 5, 2020
Outbreak of multi-drug-resistant (MDR) Shigella flexneri in northern Australia due to an endemic regional clone acquiring an IncFII plasmidChristine J D Guglielmino, Asha Kakkanat, Brian M Forde, et al.
BMC Microbiology|April 13, 2022
Standard rectal swabs as a surrogate sample for gut microbiome monitoring in intensive careSanmarié Schlebusch, Rikki M A Graham, Amy V Jennison, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumorsC A Johnson, D Kilpatrick, R von Roemeling, et al.
Infection and Immunity|January 31, 2007
Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse modelAbiodun D Ogunniyi, Kim S LeMessurier, Rikki M A Graham, et al.
Epidemiology and Infection|March 27, 2014
Molecular characterization of an Australian serotype 1 Streptococcus pneumoniae outbreakM Staples, R M A Graham, A V Jennison, et al.
Biochemical Pharmacology|August 4, 1992
Studies on the molecular pharmacology of GR63178A. A novel pentacyclic pyrolloquinone anticancer drugJ Cummings, M A Graham, B M Hoey, et al.
Cancer Research|May 15, 1992
Phase I and pharmacokinetic study of rhizoxinD Bissett, M A Graham, A Setanoians, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancerN Kemeny, W Tong, M Gonen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksS Senan, R Rampling, M A Graham, et al.
Cancer Research|August 1, 1997
Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxiaE O Aboagye, R J Maxwell, A B Kelson, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 5, 2020
Outbreak of multi-drug-resistant (MDR) Shigella flexneri in northern Australia due to an endemic regional clone acquiring an IncFII plasmidChristine J D Guglielmino, Asha Kakkanat, Brian M Forde, et al.
BMC Microbiology|April 13, 2022
Standard rectal swabs as a surrogate sample for gut microbiome monitoring in intensive careSanmarié Schlebusch, Rikki M A Graham, Amy V Jennison, et al.
Pageof 12